RECEPTORAI – Weekly Recap

RECEPTORAI featured prominently this week for advances in its AI-driven drug discovery platform and an active conference schedule aimed at expanding partnerships. The company is positioning its technology to help pharma and biotech clients tackle challenging targets and complex modalities across small molecules, peptides, macrocycles, and protein–protein interactions.

RECEPTORAI reported a case study on a difficult DNA repair and recombination protein where traditional methods struggled to find viable binders. By structuring a virtual library of up to 10¹⁶ compounds around DNA-like pharmacophores and using its StratAI decision engine with ArtiDock and physics-based methods, the firm identified 18 diverse hits below 10 μM, including a lead with 1.6 μM IC50.

Management framed this workflow as evidence that the platform can address broad, shallow and highly charged protein surfaces, where pocket-focused chemistry is less effective. If similar results are achieved in additional programs, this capability could make RECEPTORAI a sought-after partner for de-risking complex discovery projects and may support higher-value collaborations over time.

The company also highlighted technical progress in pocket-aware AI docking, moving beyond generic scoring functions toward binding-site–driven approaches. Its workflow combines high-throughput fragment mapping with 119 probes, induced-fit refinement, and mixed-solvent molecular dynamics to characterize binding pockets before applying the ArtiDock AI docking engine.

This pocket-aware strategy is designed to improve pose prediction and binding energy estimates, particularly for flexible or poorly characterized sites. Enhanced docking accuracy could strengthen RECEPTORAI’s value proposition in virtual screening campaigns and lead optimization, differentiating it in the crowded AI-enabled discovery market.

In structural biology, RECEPTORAI flagged potential biases in AlphaFold 3, citing concerns that high-confidence predictions may remain stable under disruptive mutations due to template reliance. The company positions its own workflows as a corrective layer to mitigate implausible interfaces and disordered regions, aiming to improve the reliability of structural inputs for downstream design.

Peptide therapeutics remain another focus area, with RECEPTORAI expanding membrane permeability modeling and gastrointestinal permeability optimization capabilities. A proprietary physics-based approach that generates conformational ensembles across aqueous and membrane environments feeds an AI predictor intended to address permeability bottlenecks in macrocyclic and cyclic peptides.

On the business development front, RECEPTORAI plans to attend the TIDES 2026 conference in Boston to meet peptide therapeutics and AI drug discovery teams. In parallel, the company will participate in Bio-IT World 2026, where CEO Alan Nafiev and Head of Business Development Askar Kuchumov expect to engage pharma, biotech, and technology partners around its adaptive discovery systems.

Across these events, RECEPTORAI is emphasizing decision-support tools that prioritize molecules and experiments and optimize resource allocation in complex R&D programs. While no specific deals or financial metrics were disclosed, increased conference visibility and technical differentiation may support a stronger partnership pipeline and future commercialization.

Overall, the week underscored RECEPTORAI’s dual focus on deepening its AI and physics-based capabilities for difficult targets and actively seeking collaborations in peptides and broader drug discovery. These efforts appear geared toward reinforcing the company’s competitive position in AI-enabled discovery and structural modeling services.